← Back to Screener
Corvus Pharmaceuticals, Inc. (CRVS)
Price$11.12
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)13.34%
Price vs S&P 500 (4W)-28.48%
VGM Score54.06
Market Capitalization$935.09M
All Metrics
Book Value / Share (Quarterly)$2.86
P/TBV (Annual)1.28x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.42
Price vs S&P 500 (YTD)36.26%
EPS (TTM)$-0.53
10-Day Avg Trading Volume1.54M
EPS Excl Extra (TTM)$-0.53
EPS (Annual)$-0.19
ROI (Annual)-24.97%
Cash / Share (Quarterly)$2.81
ROA (Last FY)-21.49%
EBITD / Share (TTM)$-0.58
ROE (5Y Avg)-80.85%
Cash Flow / Share (Annual)$-0.44
P/B Ratio3.89x
P/B Ratio (Quarterly)5.11x
Net Income / Employee (Annual)$-527,000
Net Interest Coverage (TTM)-44.37x
ROA (TTM)-35.75%
EPS Incl Extra (Annual)$-0.19
Current Ratio (Annual)6.21x
Quick Ratio (Quarterly)19.68x
3-Month Avg Trading Volume1.49M
52-Week Price Return184.40%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.90
52-Week High$26.95
EPS Excl Extra (Annual)$-0.19
CapEx CAGR (5Y)16.81%
Tangible BV CAGR (5Y)-7.93%
26-Week Price Return21.27%
Quick Ratio (Annual)6.12x
13-Week Price Return-30.76%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)19.81x
Enterprise Value$894.98M
Book Value / Share Growth (5Y)-20.24%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.76
3-Month Return Std Dev80.07%
Net Income / Employee (TTM)$-1,523,000
ROE (Last FY)-24.97%
Net Interest Coverage (Annual)25.34x
EPS Basic Excl Extra (Annual)$-0.19
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.53
Receivables Turnover (Annual)0.00x
ROI (TTM)-38.92%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.21
Price vs S&P 500 (52W)160.03%
Year-to-Date Return44.42%
5-Day Price Return-7.95%
EPS Normalized (Annual)$-0.19
ROA (5Y Avg)-54.26%
Month-to-Date Return-10.39%
Cash Flow / Share (TTM)$-0.63
EBITD / Share (Annual)$-0.54
ROI (5Y Avg)-80.85%
EPS Basic Excl Extra (TTM)$-0.53
P/TBV (Quarterly)1.62x
P/B Ratio (Annual)9.40x
Book Value / Share (Annual)$0.82
Price vs S&P 500 (13W)-39.01%
Beta0.99x
Revenue / Share (TTM)$0.00
ROE (TTM)-38.92%
52-Week Low$3.55
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.15est. -0.15
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.31
4.31
4.31
4.23
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CRVSCorvus Pharmaceuticals, Inc. | — | — | C | $11.12 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing immunotherapies that target proteins critical to T cell function and activation. Its lead candidate, soquelitinib, is designed to inhibit ITK to modulate T cell responses in immune-mediated disorders. The company also develops Ciforadenant and Mupadolimab, addressing complementary immune-regulation pathways.